1. Ets-1 enhances tumor migration through regulation of CCR7 expression.
- Author
-
Fang LW, Kao YH, Chuang YT, Huang HL, and Tai TS
- Subjects
- Cell Line, Tumor, Cell Movement genetics, Chemokine CCL19 genetics, Chemokine CCL19 metabolism, Chemokine CCL21 genetics, Chemokine CCL21 metabolism, Female, Humans, NF-kappa B metabolism, Proto-Oncogene Protein c-ets-1 genetics, Signal Transduction genetics, Signal Transduction physiology, Gene Expression Regulation, Neoplastic genetics, Proto-Oncogene Protein c-ets-1 metabolism, Receptors, CCR7 genetics, Receptors, CCR7 metabolism
- Abstract
Ets-1 is a prototype of the ETS protein family. Members of the ETS protein family contain a unique ETS domain. Ets-1 is associated with cancer progression and metastasis in many types of cancer. Many studies have shown a link between elevated expression of Ets-1 in cancer biopsies and poor survival. CCR7 is a chemokine that binds to specific ligand CCL21/CCL19. CCR7 expression is associated with tumor metastasis and infiltration into lymph nodes. The objective of this study was to test whether Ets-1 could regulate CCR7 expression and enhance tumor metastasis. Our data showed that CCR7 expression was downregulated in Ets-1-deficient T cells upon T-cell stimulation. Overexpression of Ets-1 increased CCR7 expression in breast cancer cell lines. In contrast, knockdown of Ets-1 reduced CCR7 expression. Ets-1 could directly bind to CCR7 promoter and mediate CCR7 expression in luciferase reporter assays and chromatin immunoprecipitation assays. Transactivation activity of Ets-1 was independent of the Pointed domain of Ets-1. Ets-1 could also enhance NF-κB and CBP transactivation of CCR7 promoter. Our results also showed that Ets-1 could modulate cancer cell transmigration by altering CCR7 expression in transwell assay and wound healing assay. Taken together, our data suggest that Ets-1 can enhance CCR7 expression and contribute to tumor cell migration. [BMB Reports 2019; 52(9): 548-553].
- Published
- 2019